安络化纤丸联合复方牛胎肝提取物片治疗乙型肝炎肝硬化的疗效观察

目的探讨安络化纤丸联合复方牛胎肝提取物片治疗乙型肝炎肝硬化临床疗效。方法选取2013年5月—2015年5月在上海市普陀区中心医院接受治疗的乙型肝炎肝硬化患者84例,根据治疗方案的差别分为对照组和治疗组,每组各42例。对照组口服复方牛胎肝提取物片,2片/次,3次/d。治疗组在对照组基础上口服安络化纤丸,1袋/次,2次/d。两组患者均治疗6个月。观察两组的临床疗效,比较两组治疗前后肝功能、肝纤维化指标及门静脉系统指标变化情况。结果治疗后,对照组和治疗组的总有效率分别为76.19%、92.86%,两组总有效率比较差异有统计学意义(P0.05)。治疗后,两组患者丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)和总胆红素(TBIL)水平均显著下降,白蛋白(ALB)水平显著升高,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者透明质酸(HA)、黏连蛋白(LN)、Ⅲ型前胶原(PC-III)和Ⅳ型胶原(C-IV)水平均显著下降,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者门静脉内径、脾脏厚度及脾静脉宽度均下降,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论安络化纤丸联合复方牛胎肝提取物片治疗乙型肝炎肝硬化的临床疗效显著,能有效改善患者肝功能和肝纤维化,具有一定的临床推广应用价值。

Clinical observation of Anluo Huaxian Pills combined with Compound Embryonic Bovine Liver Extract Tablets in treatment of HBV-related hepatic cirrhosis

Objective To investigate the clinical effect of Anluo Huaxian Pills combined with Compound Embryonic Bovine Liver Extract Tablets in treatment of HBV-related hepatic cirrhosis. Methods Patients (84 cases) with HBV-related hepatic cirrhosis in Shanghai Putuo District Central Hospital from May 2013 to May 2015 were enrolled in this study. According to the different treatment plans, patients were divided into control group and treatment group, and each group had 42 cases. The patients in the control group were po administered with Compound Embryonic Bovine Liver Extract Tablets, 2 tablets/time, three times daily. The patients in the treatment group were po administered with Anluo Huaxian Pills on the basis of control group, 6 bag/time, twice daily. The patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the changes of liver function, liver fibrosis indexes, and portal vein system indexes in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 76.19% and 92.86%, respectively, and there was difference between two groups (P< 0.05). After treatment, the levels of ALT, AST, and TBIL in two groups were significantly decreased, but the level of ALB in two groups was significantly increased, and the differences were statistically significant in the same group (P< 0.05). These observational indexes in the treatment group were better than those in the control group, with significant differences between two groups (P< 0.05). After treatment, the level of HA, LN, PC-III, and C-IV in two groups were significantly decreased, and the differences were statistically significant in the same group (P< 0.05). These observational indexes in the treatment group were better than those in the control group, with significant differences between two groups (P< 0.05). After treatment, the portal vein diameter, spleen thickness, and splenic vein width in two groups were significantly decreased, and the differences were statistically significant in the same group (P< 0.05). These observational indexes in the treatment group were better than those in the control group, with significant differences between two groups (P< 0.05). Conclusion Anluo Huaxian Pills combined with Compound Embryonic Bovine Liver Extract Tablets has clinical curative effect in treatment of HBV-related hepatic cirrhosis, and can improve liver function and liver fibrosis, which has a certain clinical application value.